MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Abbott Laboratories

Uždarymo kaina

SektoriusSveikatos priežiūra

123.73 2.37

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

123.53

Max

124.48

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-7.9B

1.3B

Pardavimai

-616M

10B

P/E

Sektoriaus vid.

17.147

39.857

Pelnas, tenkantis vienai akcijai

1.09

Dividendų pajamingumas

1.74

Pelno marža

12.792

Darbuotojai

114,000

EBITDA

-324M

2.7B

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+17.79% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

1.74%

2.42%

Kitas uždarbis

2025-10-15

Kitas dividendų mokėjimo data

2025-08-15

Kita Ex Dividend data

2025-10-14

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

1.9B

230B

Ankstesnė atidarymo kaina

121.36

Ankstesnė uždarymo kaina

123.73

Naujienos nuotaikos

By Acuity

35%

65%

93 / 376 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

Abbott Laboratories Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-17 12:10; UTC

Uždarbis

Abbott Labs Pares Outlook, Logs 2Q Profit Gains

2025-04-16 16:21; UTC

Uždarbis

Abbott Labs Bracing for Tariffs as Profits Rise -- Update

2025-04-16 12:14; UTC

Uždarbis

Abbott Labs 1Q Profit Jumps on Gains in Nutrition, Medical Devices

2025-07-17 13:14; UTC

Uždarbis

Abbott Labs Stock Falls After Earnings. Why Rising Sales Fail to Lift Shares. -- Barrons.com

2025-07-17 12:16; UTC

Uždarbis

Abbott Labs Stock Dives After Earnings Miss. Why Rising Sales Fail to Lift Shares. -- Barrons.com

2025-07-17 11:32; UTC

Uždarbis

Abbott Labs Sees 3Q Adj EPS $1.28-Adj EPS $1.32 >ABT

2025-07-17 11:32; UTC

Uždarbis

Abbott Labs: See Momentum Carrying Into 2026 >ABT

2025-07-17 11:31; UTC

Uždarbis

Abbott Labs Sees 2025 Organic Sales Up 7.5%-8%, Excluding Covid-19 Testing-Related Sales >ABT

2025-07-17 11:30; UTC

Uždarbis

Abbott Labs 2Q Organic Sales Rose 6.9% >ABT

2025-07-17 11:30; UTC

Uždarbis

Abbott Labs 2Q Adjusted Operating Margin 22.9% >ABT

2025-07-17 11:30; UTC

Uždarbis

Abbott Labs 2Q Adjusted Gross Margin 57% >ABT

2025-07-17 11:30; UTC

Uždarbis

Abbott Labs 2Q Organic Sales Growth Up 6.9% >ABT

2025-07-17 11:30; UTC

Uždarbis

Abbott Labs 2Q Sales $11.14B >ABT

2025-07-17 11:30; UTC

Uždarbis

Abbott Labs 2Q Net $1.78B >ABT

2025-07-17 11:30; UTC

Uždarbis

Abbott Labs 2Q Adj EPS $1.26 >ABT

2025-07-17 11:30; UTC

Uždarbis

Abbott Labs Sees FY Adj EPS $5.10-Adj EPS $5.20 >ABT

2025-07-17 11:30; UTC

Uždarbis

Abbott Labs 2Q EPS $1.01 >ABT

2025-07-17 09:08; UTC

Karštos akcijos

Stocks to Watch Thursday: TSMC, United Airlines, Sarepta -- WSJ

2025-07-01 18:41; UTC

Įsigijimai, susijungimai, perėmimai

How DexCom, Insulet, and Amedisys Might Be Affected by Medicare Cuts -- Barrons.com

2025-04-16 15:09; UTC

Rinkos pokalbiai

Abbott Says Tariffs Killed Chances of an Outlook Raise -- Market Talk

2025-04-16 14:17; UTC

Uždarbis

Abbott Laboratories Stock Rises as First-Quarter Earnings Surpass Expectations -- Barrons.com

2025-04-16 11:34; UTC

Uždarbis

Abbott Labs 1Q Gross Margin of 52.8 % of Sales; Adj Gross Margin of 57.1 % >ABT

2025-04-16 11:33; UTC

Uždarbis

Abbott Labs Projects FY25 Adj Operating Margin to Be 23.5% to 24.0% of Sales >ABT

2025-04-16 11:32; UTC

Uždarbis

Abbott Labs Backs FY25 Adj EPS $5.05-Adj EPS $5.25 >ABT

2025-04-16 11:32; UTC

Uždarbis

Abbott Labs Sees 2Q Adj EPS $1.23-Adj EPS $1.27 >ABT

2025-04-16 11:31; UTC

Uždarbis

Abbott Labs Projects FY25 Organic Sales Growth of 7.5% to 8.5% >ABT

2025-04-16 11:30; UTC

Uždarbis

Abbott Reaffirms Full-Yr Guidance

2025-04-16 11:30; UTC

Uždarbis

Abbott Labs 1Q Organic Sales Growth Up 6.9% >ABT

2025-04-16 11:30; UTC

Uždarbis

Abbott Labs 1Q Sales $10.36B >ABT

2025-04-16 11:30; UTC

Uždarbis

Abbott Labs 1Q Net $1.33B >ABT

Akcijų palyginimas

Kainos pokytis

Abbott Laboratories Prognozė

Kainos tikslas

By TipRanks

17.79% į viršų

12 mėnesių prognozė

Vidutinis 145.67 USD  17.79%

Aukščiausias 159 USD

Žemiausias 135 USD

Remiantis 19 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Abbott Laboratories kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

19 ratings

16

Pirkti

3

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

132.82 / 134.43Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bullish Evidence

Vidutinės trukmės periodas

Neutral Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

93 / 376 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.